Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML0142

Sigma-Aldrich

Valsartan

≥98% (HPLC)

Sinônimo(s):

N-(1-Oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C24H29N5O3
Número CAS:
137862-53-4
Peso molecular:
435.52
Número MDL:
MFCD00865840
Código UNSPSC:
12352200
ID de substância PubChem:
329825190
NACRES:
NA.77

Ensaio

≥98% (HPLC)

Formulário

powder

atividade óptica

[α]/D -55 to -70°, c = 1 in methanol

condição de armazenamento

desiccated

cor

white to tan

solubilidade

DMSO: ≥20 mg/mL

originador

Novartis

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CCCCC(=O)N(Cc1ccc(cc1)-c2ccccc2-c3nnn[nH]3)[C@@H](C(C)C)C(O)=O

InChI

1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

chave InChI

ACWBQPMHZXGDFX-QFIPXVFZSA-N

Informações sobre genes

human ... AGTR1(185)

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Mice were treated with valsartan to study the role of Ang II-dependent pathway in aldosterone-related effects.

Ações bioquímicas/fisiológicas

Valsartan is an Angiotensin II type 1 (AT1) receptor antagonist and anti-hypertensive. Valsartan renders protection against heart attack and stroke resulting from abrupt increase in blood pressure. Valsartan reduces myocardial-infarction-related complications in heart attack survivors.

Características e benefícios

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palavra indicadora

Warning

Frases de perigo

H336,H361d

Declarações de precaução

P201 - P308 + P313

Classificações de perigo

Repr. 2 - STOT SE 3

Órgãos-alvo

Central nervous system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
123M4716V
091M4728V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 8

1 of 8

Eprosartan mesylate ≥98% (HPLC)

Sigma-Aldrich

E2535

Eprosartan mesylate

Valsartan for peak identification European Pharmacopoeia (EP) Reference Standard

Y0001131

Valsartan for peak identification

Ramipril ≥98% (HPLC)

Sigma-Aldrich

R0404

Ramipril

Olmesartan ≥98% (HPLC)

Sigma-Aldrich

SML1394

Olmesartan

Valsartan Related Compound A Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1875

Valsartan Related Compound A

ZD7155 hydrochloride ≥97% (HPLC)

Sigma-Aldrich

SML2114

ZD7155 hydrochloride

Autocamtide 2-related inhibitory peptide ≥97% (HPLC), lyophilized powder

Sigma-Aldrich

A4308

Autocamtide 2-related inhibitory peptide

Lisinopril ≥98% (HPLC)

Sigma-Aldrich

L6292

Lisinopril

N M Kaplan
American family physician, 60(4), 1185-1190 (1999-10-03)
The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) includes recommendations for the assessment of overall cardiovascular risk and the need for active antihypertensive drug therapy. Once the decision to
Bodh I Jugdutt
Vascular health and risk management, 2(2), 125-138 (2007-02-27)
Survivors of myocardial infarction (MI) are at high risk of disability and death. This is due to infarct-related complications such as heart failure, cardiac remodeling with progressive ventricular dilation, dysfunction, and hypertrophy, and arrhythmias including ventricular and atrial fibrillation. Angiotensin
Frédéric Michel et al.
Circulation, 109(16), 1933-1937 (2004-04-14)
We analyzed the role of aldosterone in ischemia-induced neovascularization and the involvement of angiotensin II (Ang II) signaling in this effect. Ischemia was induced by right femoral artery ligature in mice treated or not with aldosterone (4.5 microg/day), aldosterone plus
Teun van der Bom et al.
Circulation, 127(3), 322-330 (2012-12-19)
The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo
Arjan J Kwakernaak et al.
Atherosclerosis, 226(2), 459-465 (2012-12-25)
LDL-receptor deficiency may provide a mechanism which contributes to atherogenic lipoprotein abnormalities in experimental nephrosis and in humans with glomerular proteinuria. The proprotein convertase subtilisin-kexin type 9 (PCSK9) pathway plays a key role in lipoprotein metabolism by promoting LDL-receptor degradation.
Exibir todos os documentos relacionados

Conteúdo relacionado

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica